Durvalumab Induces Sustained Survival Benefit After Concurrent Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Pujol JL. J Clin Oncol 2022 Mar 3:JCO2200204. doi: 10.1200/JCO.22.00204.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Pujol JL. Durvalumab Induces Sustained Survival Benefit After Concurrent Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol 2022 Mar 3:JCO2200204. doi: 10.1200/JCO.22.00204.
PMID: 35239424